Ovarian Carcinoma — Trials

Ovarian Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

895 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 270
Recruiting: 140
Ph III recruiting: 16
Growth YoY: +23.1%
Industry share: 31%
Top sponsor: National Cancer Institute (NCI)
Termination share: 38.7%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (145)

clinicaltrialsPublishedShowing 151–156 of 156 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT00563836	Phase II Study of the Trifunctional Antibody Catumaxomab Administered Intra- and Postoperatively in Patients With Ovarian Cancer	completed	Phase 2	41	Neovii BiotechINDUSTRY	2	Oct 3, 2012	clinicaltrials
NCT00281515	Comparison of Paclitaxel/Carboplatin and Lonafarnib to Paclitaxel/Carboplatin for First-line Treatment of Ovarian Cancer	completed	Phase 2	105	AGO Study GroupOTHER	1	Jun 29, 2012	clinicaltrials